Thursday, Laboratory Corp A reported second-quarter 2024 adjusted EPS of $3.94, up from $3.42 a year ago, beating the consensus of $3.78. Sales increased 6.2% year-over-year to $3.22 billion, beating the consensus of $3.19 billion. The increase was due to organic revenue of 3.8%, acquisitions, and net of divestitures of 2.5%, partially offset by foreign currency translation of (0.1%). The 3.8% increase in organic revenue was driven by a 4.5% increase in the company's organic Base Business, partially offset ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, reported adjusted earnings per share (EPS) of $3.94 in the second quarter of 2024, up 15.2% from the year-ago quarter's figure. The adjusted figure excludes the impact of certain amortization expenses and restructuring charges, among others. The bottom line also beat the Zacks Consensus Estimate by 4.2%. On a GAAP basis, EPS in the second quarter was $2.43, up 14.6% from last year's comparable period. Revenues Revenues in the quarter under review ...

For the quarter ended June 2024, Labcorp (LH) reported revenue of $3.22 billion, up 6.2% over the same period last year. EPS came in at $3.94, compared to $3.42 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $3.2 billion, representing a surprise of +0.78%. The company delivered an EPS surprise of +4.23%, with the consensus EPS estimate being $3.78. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectati ...

Labcorp (LH) came out with quarterly earnings of $3.94 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.42 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 4.23%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $3.46 per share when it actually produced earnings of $3.68, delivering a surprise of 6.36%. Over the last four quarters, the ...

财务业绩 - 2024年第二季度收入为32.2亿美元，同比增长6.2%[14] - 2024年第二季度调整后每股收益为3.94美元，同比增长15.2%[16] - 2024年全年收入增长预期为6.4%至7.5%，其中Invitae公司的影响约为1.0%[32] - 2024年全年调整后每股收益预期为14.30美元至14.90美元，其中Invitae公司的摊薄影响约为0.40美元[33] - 2024年全年自由现金流预期为8.5亿美元至10亿美元，其中Invitae公司的现金使用约为1.5亿美元[34] - 2024年第二季度收入为32.21亿美元，同比增长6.2%[44] - 2024年上半年收入为63.98亿美元，同比增长5.4%[44] - 2024年第二季度净利润为2.05亿美元，同比增长14.5%[45] - 2024年上半年净利润为4.33亿美元，同比增长19.3%[45] - 公司2024年第二季度和上半年收入分别为32.21亿美元和63.98亿美元，同比增长6.2%和5.4%[55] - 诊断实验室业务2024年第二季度和上半年收入分别为25.25亿美元和50.05亿美元，同比增长7.9%和6.0%[52] - 生物制药实验室服务业务2024年第二季度和上半年收入分别为7.07亿美元和14.18亿美元，同比增长1.1%和4.2%[53] - 2024年第二季度和上半年调整后营业利润分别为4.80亿美元和9.33亿美元，同比增长7.0%和4.1%[56] - 2024年第二季度和上半年调整后营业利润率分别为14.9%和14.6%[56] - 2024年第二季度和上半年经调整每股收益分别为3.94美元和7.62美元，同比增长15.2%和10.7%[61] - 2024年第二季度和上半年经营活动产生的现金流分别为5.61亿美元和5.31亿美元，同比增长59.6%和12.3%[50] - 2024年第二季度和上半年资本支出分别为1.28亿美元和2.62亿美元，同比增长24.1%和44.3%[50] - 2024年第二季度和上半年进行了3.39亿美元和29.31亿美元的企业收购[50] - 2024年第二季度和上半年支付了1.00亿美元和1.23亿美元的股息[50] 业务发展 - 公司获得FDA批准用于血友病B基因疗法的伴随诊断[8] - 公司推出首个三个月孕期子痫前期筛查检测[9] - 公司扩大精准肿瘤组合服务,包括在日内瓦和上海提供Labcorp® Tissue Complete和添加OmniSeq INSIGHT液体活检基因组分析服务[10] - 公司推出Labcorp Global Trial Connect,提供中央实验室解决方案以加快临床试验[11] - 公司扩大Labcorp OnDemand服务,新增多项检测[12] 财务状况 - 2024年6月30日现金及现金等价物余额为2.65亿美元[49] - 2024年6月30日应收账款净额为20.89亿美元[49] - 2024年6月30日商誉净额为62.20亿美元[49] - 2024年6月30日无形资产净额为33.32亿美元[49] - 2024年6月30日总资产为167.12亿美元[49] - 2024年6月30日总负债为86.92亿美元[49] 重组和整合 - 公司进行了业务重组和精简冗余职位及设施,涉及LaunchPad计划、Fortrea公司的分拆以及收购或出售业务[1] - 公司发生了与收购和处置相关的成本,包括尽职调查、法律和咨询费用、保留奖金、延迟合同或许可转让的影响以及其他整合或处置相关活动[1] - 公司发生了与LaunchPad计划实施相关的非资本化成本,包括系统整合、流程整合以及各种业务流程改进举措的咨询费用[1] - 公司为Fortrea的分拆和剩余Labcorp业务的重组发生了各种成本[1] - 公司对某些固定资产和资本化软件成本进行了减值,因为这些资产已不再为业务所用[1] - 公司从Fortrea收取了过渡服务费,用于提供行政和IT系统支持,但提供这些服务的成本计入了营业收入[1] - 公司对Fortrea分拆后的临床开发和商业化服务业务进行了调整[1] 其他 - 公司对一些投资公司或基金进行了投资,并记录了相关的收益和损失[1] - 公司出售了Beacon Laboratory Benefits Solutions业务并记录了收益[1] - 公司因结算美国养老金计划的某些义务而产生了费用[1]

Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94 versus $3.42 Free Cash Flow: $432.9 million versus $58.2 million Updated Full-Year 2024 Guidance: Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0% Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40 Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash us ...

BURLINGTON, N.C., and FREMONT, Calif., July 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeqTM technology to explore new whole genome sequencing (WGS) clinical applications, including molecular residual disease (MRD) in patients with early-stage solid tumor cancers. Labcorp recently introduced Labcorp® Plasma Detect™, the first ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, is slated to report second-quarter 2024 results on Aug 1 before market open.In the last reported quarter, the company’s adjusted earnings of $3.68 topped the Zacks Consensus Estimate by 6.36%. Labcorp surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 1.38%.Q2 EstimatesThe Zacks Consensus Estimate for Labcorp’s second-quarter 2024 revenues is pegged at $3.20 billion. This suggests a 5 ...

文章核心观点 - Zacks Premium是一个研究服务,提供多种工具帮助投资者更有信心地投资股票市场[1][2] - Zacks Style Scores是一个评分系统,根据股票的价值、成长和动量特征给予A-F的评分,评分越高表示越有可能超越市场[3][4] - Zacks Rank是一个股票评级模型,根据盈利预期变化来评估股票,Rank为1或2且Style Scores为A或B的股票有最高的成功概率[9][10][12] 行业总结 - 公司是一家领先的医疗诊断公司,提供全面的临床实验室服务和整个药物开发支持[15] - 公司在2015年收购了一家提供广泛早期和晚期产品开发服务的药物开发服务公司[15] - 公司目前的Zacks Rank为3(Hold),VGM Score为B,Value Score为A,表现较好[15][16] - 最近一个分析师上调了公司2024财年的盈利预测,预测每股收益为14.87美元,公司平均盈利惊喜为1.4%[17]

BURLINGTON, N.C., July 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast ...